Bellus Stock Insiders

BLU
 Stock
  

USD 10.23  0.35  3.31%   

Bellus Health employes about 40 people. The company is managed by 20 executives with total tenure of roughly 218 years, averaging almost 10.0 years of service per executive having 2.0 employees per reported executive. Break down Bellus Health management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Bellus Health future performance.
Continue to Trending Equities.
  
  Mark Levy  CEO
Joint CEO, Executive Director
  Brett Levy  CEO
Joint CEO, Executive Director
  Laurence Nestadt  Chairman
Independent Non-Executive Chairman of the Board

Bellus Health Management Team Effectiveness

Bellus Health has Return on Asset of (20.9) % which means that on every $100 spent on asset, it lost $20.9. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (33.82) %, meaning that it generated no profit with money invested by stockholders. Bellus Health management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Bellus Health Workforce Comparison

Bellus Health is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 59,937. Bellus Health adds roughly 40.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Bellus Health Benchmark Summation

The output start index for this execution was eight with a total number of output elements of fifty-three. The Index of highest value over a specified period line plots maximum indexes of Bellus Health price series.
.

Bellus Health Notable Stakeholders

A Bellus Health stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bellus Health often face trade-offs trying to please all of them. Bellus Health's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bellus Health's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Levy - Joint CEO, Executive DirectorProfile
Brett Levy - Joint CEO, Executive DirectorProfile
Laurence Nestadt - Independent Non-Executive Chairman of the BoardProfile
Tong Teo - Non-Executive Chairman of the Board, Non-Executive Independent DirectorProfile
Kantilal Champaklal - CFOProfile
Mahtani Bhagwandas - Independent Non-Executive DirectorProfile
Jerry Vilakazi - Non-Executive Independent DirectorProfile
Gary Harlow - Independent Non-Executive DirectorProfile
Dean Suntup - Financial Director, DirectorProfile
Yusuf Mahomed - Independent Non-Executive DirectorProfile
Joe Mthimunye - Independent Non-Executive DirectorProfile
Kevin Ellerine - Non-Executive DirectorProfile
Peter Moe - Independent Non-Executive DirectorProfile
Lik Goh - Independent Non-Executive DirectorProfile
Phuti Mahanyele - Non-Executive Independent DirectorProfile
Janine Eden - Group Company SecretaryProfile
Chee Kwan - General Manager - Property DivisionProfile
Siok Lim - General Manager of Region Suppliers Pte Ltd.Profile
Peck Peng - Financial ControllerProfile
Cheng Tan - Company SecretaryProfile

About Bellus Health Management Performance

The success or failure of an entity such as Bellus Health often depends on how effective the management is. Bellus Health management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bellus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bellus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications. The company was incorporated in 1993 and is based in Laval, Canada. Bellus Health operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.
The data published in Bellus Health's official financial statements usually reflect Bellus Health's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bellus Health. For example, before you start analyzing numbers published by Bellus accountants, it's critical to develop an understanding of what Bellus Health's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bellus Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bellus Health's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bellus Health's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bellus Health. Please utilize our Beneish M Score to check the likelihood of Bellus Health's management to manipulate its earnings.

Bellus Health Workforce Analysis

Traditionally, organizations such as Bellus Health use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bellus Health within its industry.

Bellus Health Manpower Efficiency

Return on Bellus Health Manpower

Revenue Per Employee400
Revenue Per Executive800
Net Loss Per Employee1.7 M
Net Loss Per Executive3.5 M
Working Capital Per Employee792.3 K
Working Capital Per Executive1.6 M
Continue to Trending Equities. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for analysis

When running Bellus Health price analysis, check to measure Bellus Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bellus Health is operating at the current time. Most of Bellus Health's value examination focuses on studying past and present price action to predict the probability of Bellus Health's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bellus Health's price. Additionally, you may evaluate how the addition of Bellus Health to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Bellus Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bellus Health. If investors know Bellus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bellus Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bellus Health is measured differently than its book value, which is the value of Bellus that is recorded on the company's balance sheet. Investors also form their own opinion of Bellus Health's value that differs from its market value or its book value, called intrinsic value, which is Bellus Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bellus Health's market value can be influenced by many factors that don't directly affect Bellus Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bellus Health's value and its price as these two are different measures arrived at by different means. Investors typically determine Bellus Health value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bellus Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.